» Articles » PMID: 27659440

Clinical and Economic Evaluation of Multidrug-Resistant Acinetobacter Baumannii Colonization in the Intensive Care Unit

Overview
Date 2016 Sep 24
PMID 27659440
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The clinical and economic impact of multidrug-resistant (MDR) Acinetobacter baumannii colonization remains unclear. This study aimed to estimate and compare the mortality rates, length of stay (LOS), and hospitalization costs in the intensive care unit (ICU) for MDR A. baumannii colonized patients and a matched population.

Materials And Methods: We performed a retrospective propensity score matched cohort study comparing the outcomes of patients with MDR A. baumannii colonization with those of uncolonized subjects matched at the time they were admitted to the ICU between January 2012 and December 2014.

Results: During the study period, 375 (7.5%) of the 4,779 patients were colonized with MDR A. baumannii. One hundred and twenty-two MDR A. baumannii colonized patients were compared with 122 uncolonized patients using propensity score matching. MDR A. baumannii colonized patients were likely to have a higher mortality rate compared to uncolonized patients (49.2% vs 32.0%; odds ratio [OR], 3.64). A longer ICU LOS and total admission days were observed in the MDR A. baumannii colonized patient group (4.14 and 4.67 days increase, OR 1.41 and 1.19). MDR A. baumannii colonization patients had an average extra ICU and total admission cost of $1,179 (₩1,261,334) and $1,333 (₩1,422,032) according to a multivariable regression model (OR, 1.27 and 1.17). Multivariable analysis identified the factors affecting ICU cost, which included, MDR A. baumannii colonization (OR = 1.33; P = 0.001), ICU LOS (OR = 1.97; P <0.001), valvular heart disease (OR = 1.12; P = 0.005), invasive devices (OR = 1.15; P = 0.018), and surgery (OR = 1.1; P < 0.001).

Conclusion: MDR A. baumannii colonization was associated with increased mortality, LOS, and costs in the ICU. A strict infection control program including preemptive isolation for high-risk groups would be helpful for reducing the burden of this infection.

Citing Articles

Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization.

Peghin M, Givone F, De Martino M, Ali R, Graziano E, Isola M Eur J Clin Microbiol Infect Dis. 2024; 43(11):2191-2199.

PMID: 39285106 PMC: 11534838. DOI: 10.1007/s10096-024-04936-2.


Can flow cytometric measurements of reactive oxygen species levels determine minimal inhibitory concentrations and antibiotic susceptibility testing for Acinetobacter baumannii?.

Yeo J, Low J, Begam N, Leow W, Kwa A PLoS One. 2024; 19(6):e0305939.

PMID: 38913680 PMC: 11195951. DOI: 10.1371/journal.pone.0305939.


Identification and Clinical Characteristics of Community-Acquired in Patients Hospitalized for Moderate or Severe COVID-19 in Peru.

Silva-Caso W, Perez-Lazo G, Aguilar-Luis M, Morales-Moreno A, Ballena-Lopez J, Soto-Febres F Antibiotics (Basel). 2024; 13(3).

PMID: 38534701 PMC: 10967489. DOI: 10.3390/antibiotics13030266.


Risk factors for carbapenem-resistant (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization.

Cogliati Dezza F, Covino S, Petrucci F, Sacco F, Viscido A, Gavaruzzi F JAC Antimicrob Resist. 2023; 5(4):dlad096.

PMID: 37577156 PMC: 10412853. DOI: 10.1093/jacamr/dlad096.


Current Status and Prospect of Qualitative Assessment of Antibiotics Prescriptions.

Park S, Kim Y, Lee R, Kim B, Moon S, Kim H Infect Chemother. 2023; 54(4):599-609.

PMID: 36596676 PMC: 9840950. DOI: 10.3947/ic.2022.0158.


References
1.
Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M . Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse. 2008; 28(1):15-25. View

2.
Holmberg S, Solomon S, Blake P . Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987; 9(6):1065-78. DOI: 10.1093/clinids/9.6.1065. View

3.
Muto C, Jernigan J, Ostrowsky B, Richet H, Jarvis W, Boyce J . SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003; 24(5):362-86. DOI: 10.1086/502213. View

4.
Garcia-Garmendia J, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez F, Monterrubio-Villar J, Gili-Miner M . Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999; 27(9):1794-9. DOI: 10.1097/00003246-199909000-00015. View

5.
Weber S, Huang S, Oriola S, Huskins W, Noskin G, Harriman K . Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol. 2007; 28(3):249-60. DOI: 10.1086/512261. View